Matthew A. Myers

Matthew A. Myers

Auto-generated profile, based on publicly available information

Matthew A. Myers

Computational Oncology, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2020 in Blood
Verified
Journal Article
Open access
PDF file
BLBenshang Li
Benshang Li
SBSamuel W. Brady
Samuel W. Brady
XMXiaotu Ma
Xiaotu Ma
SSShuhong Shen
Shuhong Shen
YZYingchi Zhang
Yingchi Zhang
JZJinghui Zhang
Jinghui Zhang
Li and colleagues report the genomic landscape of over 100 patients with relapsed acute lymphoblastic leukemia. Analysis of diagnosis-relapse-remission trios suggest that whereas early relapse is mediated by retained subclones, late relapse is driven by mutations induced by and conferring resistance to chemotherapy.

6 September 2024 in Science
Verified
Journal Article
Closed access
LSLaksshman Sundaram
Laksshman Sundaram
AKArvind Kumar
Arvind Kumar
MZMatthew Zatzman
Matthew Zatzman
ASAdriana Salcedo
Adriana Salcedo
NRNeal Ravindra
Neal Ravindra
HSHui Shen
Hui Shen
To identify cancer-associated gene regulatory changes, we generated single-cell chromatin accessibility landscapes across eight tumor types as part of The Cancer Genome Atlas. Tumor chromatin accessibility is strongly influenced by copy number alterations that can be used to identify subclones, yet underlying cis-regulatory landscapes retain cancer type–specific features. Using organ-matched healthy tissues, we identified the “nearest healthy” cell types in diverse cancers, demonstrating that the chromatin signature of basal-like–subtype breast cancer is most similar to secretory-type luminal epithelial cells. Neural network models trained to learn regulatory programs in cancer revealed enrichment of model-prioritized somatic noncoding mutations near cancer-associated genes, suggesting that dispersed, nonrecurrent, noncoding mutations in cancer are functional. Overall, these data and interpretable gene regulatory models for cancer and healthy tissue provide a framework for understanding cancer-specific gene regulation.

19 June 2019 in Cell Systems
Verified
Journal Article
Closed access
MMMatthew A. Myers
Matthew A. Myers
GSGryte Satas
Gryte Satas
BRBenjamin J. Raphael
Benjamin J. Raphael

16 July 2025 in Nature
Verified
Journal Article
Open access
PDF file
AMAndrew William McPherson
Andrew William McPherson
IVIgnacio Vázquez-García
Ignacio Vázquez-García
MMMatthew A. Myers
Matthew A. Myers
DADuaa H. Al-Rawi
Duaa H. Al-Rawi
MZMatthew Zatzman
Matthew Zatzman
SSSohrab P. Shah
Sohrab P. Shah
Whole-genome doubling (WGD) is a common feature of human cancers and is linked to tumour progression, drug resistance, and metastasis1,2,3,4,5,6. Here we examine the impact of WGD on somatic evolution and immune evasion at single-cell resolution in patient tumours. Using single-cell whole-genome sequencing, we analysed 70 high-grade serous ovarian cancer samples from 41 patients (30,260 tumour genomes) and observed near-ubiquitous evidence that WGD is an ongoing mutational process. WGD was associated with increased cell–cell diversity and higher rates of chromosomal missegregation and consequent micronucleation. We developed a mutation-based WGD timing method called doubleTime to delineate specific modes by which WGD can drive tumour evolution, including early fixation followed by considerable diversification, multiple parallel WGD events on a pre-existing background of copy-number diversity, and evolutionarily late WGD in small clones and individual cells. Furthermore, using matched single-cell RNA sequencing and high-resolution immunofluorescence microscopy, we found that inflammatory signalling and cGAS-STING pathway activation result from ongoing chromosomal instability, but this is restricted to predominantly diploid tumours (WGD-low). By contrast, predominantly WGD tumours (WGD-high), despite increased missegregation, exhibited cell-cycle dysregulation, STING1 repression, and immunosuppressive phenotypic states. Together, these findings establish WGD as an ongoing mutational process that promotes evolvability and dysregulated immunity in high-grade serous ovarian cancer.

1 October 2025 in Nature
Verified
Journal Article
Open access
PDF file
MWMarc J. Williams
Marc J. Williams
IVIgnacio Vázquez-García
Ignacio Vázquez-García
GTGrittney Tam
Grittney Tam
MWMichelle Wu
Michelle Wu
NVNancy Varice
Nancy Varice
SSSohrab P. Shah
Sohrab P. Shah
Emergence of drug resistance is the main cause of therapeutic failure in patients with high-grade serous ovarian cancer (HGSOC)1. To study drug resistance in patients, we developed CloneSeq-SV, which combines single-cell whole-genome sequencing2 with targeted deep sequencing of clone-specific genomic structural variants in time-series cell-free DNA. CloneSeq-SV exploits tumour clone-specific structural variants as highly sensitive endogenous cell-free DNA markers, enabling the relative abundance measurements and evolutionary analysis of co-existing clonal populations over the therapeutic time course. Here, using this approach, we studied 18 patients with HGSOC over a multi-year period from diagnosis to recurrence and showed that drug resistance typically arose from selective expansion of a single or small subset of clones present at diagnosis. Drug-resistant clones frequently showed interpretable and distinctive genomic features, including chromothripsis, whole-genome doubling, and high-level amplifications of oncogenes such as CCNE1, RAB25, MYC and NOTCH3. Phenotypic analysis of matched single-cell RNA sequencing data3 indicated pre-existing and clone-specific transcriptional states such as upregulation of epithelial-to-mesenchymal transition and VEGF pathways, linked to drug resistance. In one notable case, clone-specific ERBB2 amplification affected the efficacy of a secondary targeted therapy with a positive patient outcome. Together, our findings indicate that drug-resistant states in HGSOC pre-exist at diagnosis, leading to positive selection and reduced clonal complexity at relapse. We suggest these findings motivate investigation of evolution-informed adaptive treatment regimens to ablate drug resistance in future HGSOC studies.

8 October 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
KMKatelyn M. Mullen
Katelyn M. Mullen
JHJungeui Hong
Jungeui Hong
MAMarc Attiyeh
Marc Attiyeh
AHAkimasa Hayashi
Akimasa Hayashi
HSHitomi Sakamoto
Hitomi Sakamoto
CIChristine A. Iacobuzio-Donahue
Christine A. Iacobuzio-Donahue
The genomic features of pancreatic ductal adenocarcinoma (PDAC) have been well described, yet the evolutionary contexts within which these features occur remain unexplored. We studied genome landscapes, phylogenies, and clonal compositions of 91 PDACs in relation to clinicopathologic features. There was no difference in the number of driver mutations or evolutionary timing when each mutation occurred. High truncal density, a metric of the accumulation of somatic mutations in the lineage that gave rise to each PDAC, was significantly associated with worse overall survival. Polyclonal, monoclonal, or mixed polyclonal/monoclonal metastases were identified across the cohort, highlighting multiple forms of intertumoral heterogeneity. Advanced stage and treated PDACs had higher odds of being polyclonal, whereas oligometastatic PDACs had fewer driver alterations, a lower fractional allelic loss, and increased likelihood of being monoclonal. In sum, our findings reveal novel insights into the dynamic nature of the PDAC genome beyond established genetic paradigms. Significance: Although the pancreatic cancer genome has been described, it has not been explored with respect to stages of diagnosis or treatment bottlenecks. We now describe and quantify the genomic features of PDAC in the context of evolutionary metrics and in doing so have identified a novel prognostic biomarker.